Sulodexide for diabetic nephropathy: another one bites the dust

Editorial

Andrew A House et al. Am J Kidney Dis. 2011 Nov.

. 2011 Nov;58(5):692-4.

doi: 10.1053/j.ajkd.2011.08.011.

No abstract available

Comment in

Discounting the efficacy of sulodexide in diabetic nephropathy is premature.
Gambaro G. Gambaro G. Am J Kidney Dis. 2012 Jul;60(1):169-70. doi: 10.1053/j.ajkd.2012.01.029. Am J Kidney Dis. 2012. PMID: 22709598 No abstract available.
Surrogate versus clinical end points and venture capital companies: the doubts of a clinician.
Gaddi AV, Benedetto D. Gaddi AV, et al. Am J Kidney Dis. 2012 Jul;60(1):170; author reply 170-1. doi: 10.1053/j.ajkd.2012.03.022. Am J Kidney Dis. 2012. PMID: 22709600 No abstract available.

Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial.
Lewis EJ, Lewis JB, Greene T, Hunsicker LG, Berl T, Pohl MA, de Zeeuw D, Heerspink HL, Rohde RD, Atkins RC, Reutens AT, Packham DK, Raz I; Collaborative Study Group. Lewis EJ, et al. Am J Kidney Dis. 2011 Nov;58(5):729-36. doi: 10.1053/j.ajkd.2011.06.020. Epub 2011 Aug 26. Am J Kidney Dis. 2011. PMID: 21872376 Clinical Trial.